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Abstract To test the Kirsten-Ras (Ki-Ras) alternative prenyla-
tion hypothesis in malignant transformation, we used a novel
farnesyltransferase inhibitor competitive to farnesyl-pyrophos-
phate, RPR130401, and a CaaX peptidomimetic geranylger-
anyltransferase-1 inhibitor GGTI-298. In Ki-Ras-overexpressing
transformed adrenocortical cells, RPR130401 at 1^10 WM
inhibited very efficiently the [3H]farnesyl but not [3H]geranyl-
geranyl transfer to Ras. However, proliferation of these cells was
only slightly sensitive to RPR130401 (IC50 = 30 WM). GGTI-298
inhibited the growth of these cells with an IC50 of 11 WM but cell
lysis was observed at 15 WM. The combination of 10 WM
RPR130401 and 10 WM GGTI-298 inhibited efficiently (80%)
cell proliferation. These combined inhibitors but not each
inhibitor alone blocked the cell cycle in G0/G1 and disrupted
MAP kinase activation. Thus, combination of two inhibitors, at
non-cytotoxic concentrations, acting on the farnesyl-pyrophos-
phate binding site of the farnesyltransferase and the CaaX
binding site of the geranylgeranyltransferase-1 respectively is an
efficient strategy for disrupting Ki-Ras tumorigenic cell pro-
liferation.
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1. Introduction
Over the last decade, protein prenylation has been a focus
of many scienti¢c investigations because several proteins in-
volved in cell cycle control and di¡erentiation, including Ras
proteins, are post-translationally modi¢ed by the isoprenoids
farnesyl and geranylgeranyl [1]. Furthermore, prenylation of
oncogenic Ras proteins is required for their tumorigenesis [2].
Mammalian cells express three types of ras genes (Ha-, N- and
Ki-ras) [3]. About 30% of all human cancers express mutated
Ras proteins, the most prevalent form being of the Ki-type [4].
Translocation of Ras p21 to the plasma membrane due to
post-translational modi¢cations was shown to be essential
for its function [1]. Inhibition of prenylation of mutated Ras
results in an accumulation of a cytosolic protein which does
not have a tumorigenic function. Two di¡erent prenyl groups,
farnesyl (C15) and geranylgeranyl (C20), were found to be
attached covalently to the cysteinyl residue at the carboxyl-
terminus of proteins that end in a CaaX motif (C = Cys,
a = aliphatic residue and X = an aminoacyl residue such as
Ser, Met or Leu). Prenyl transfers are catalyzed by protein
farnesyltransferase (FTase), preferring Ser or Met, and pro-
tein geranylgeranyltransferase-1 (GGTase-1), preferring Leu
at the X position [1]. Farnesylation is the main prenylation
of Ras proteins and several FTase inhibitors were shown to
block selectively processing and signaling of oncogenic Ha-
Ras [5]. Nevertheless, oncogenic Kirsten-Ras (Ki-Ras) B
prenylation is less sensitive to FTase inhibitors [6]. It was
reported that the Ki-RasB protein can be geranylgeranylated
by GGTase-1 in vitro [6] and that its prenylation was dis-
rupted in whole cells by a potent inhibitor of GGTase-1 [7].
In a previous study, we showed that overexpressed Ki-Ras
protein was geranylgeranylated as well as farnesylated in
ras-transformed adrenocortical (RTAC) cells [8]. Other stud-
ies have shown that Ki-RasB was geranylgeranylated only
when cells were treated with FTase inhibitors [9,10]. Our
and other ¢ndings suggest that the Ki-Ras protein is prenyl-
ated by an alternative pathway using GGTase-1. Geranylger-
anylation of Ras occurs when either FTase is blocked by
FTase inhibitors, deprived from the farnesyl-pyrophosphate
(FPP) substrate or saturated by an excess of Ras proteins.
Whether geranylgeranylated Ras is as e⁄cient as farnesylated
Ras at inhibiting cell proliferation is not yet known. The dis-
covery of the novel potent FTase inhibitor benzoperhydroi-
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soindole (BPHI) which is competitive to FPP and the avail-
ability of a potent CaaX-competitive GGTase-1 inhibitor
(GGTI-298) prompted us to test the Ki-Ras alternative
prenylation hypothesis.
In this article, we report the e¡ects of BPHI FTase inhib-
itors on cell proliferation and on prenylation of Ras in Ki-
Ras-overexpressing RTAC cells. BPHI blocked very e⁄ciently
the farnesyl transfer to Ras but not that of the geranylgeranyl
moiety. However, BPHI only slightly decreased RTAC cell
proliferation. Although GGTI-298 alone inhibited cell
growth, we found that suppression of mitogen-activated pro-
tein (MAP) kinase activation and arrest of the cell cycle in the
G0/G1 phase requires both GGTI-298 and BPHI. Thus, these
results suggest that a potential strategy to block e⁄ciently Ki-
Ras-dependent tumorigenic cell growth is to use the combined
action of a peptidomimetic GGTase-1 inhibitor and a FPP-
competitive FTase inhibitor.
2. Materials and methods
2.1. FTase, GGTase-1 and 3-hydroxy-3-methyl-glutaryl-coenzyme A
(HMG-CoA) reductase inhibitors
The BPHI derivative dextrogyre enantiomers RPR130401 and
RPR115135 (Rho“ne-Poulenc Rorer, Vitry-sur-Seine, France) were
synthesized and enantiomers were resolved through high performance
liquid chromatography on chiral phase as described [11]. The synthe-
sis of FTase-speci¢c (FTI-277) and GGTase-1-speci¢c (GGTI-298)
peptidomimetics was described previously [5,7,12^14]. HMG-CoA re-
ductase inhibitors lovastatin and simvastatin were kindly provided by
Merck Sharp and Dohme Research Laboratories (Rahway, NJ,
USA).
2.2. Cell lines and cell culture
The RTAC cells, producing Ha-Ras-V12 and overexpressing Ki-
Ras, were obtained from newborn rat adrenals by transfection with
a mutated Ha-rasEJ as described previously [15]. Y1 mice adrenal
tumor cells, overexpressing Ki-Ras, and T24 human bladder tumor
cells (expressing Ha-Ras-V12) were purchased from the American
Tissue Collection (Rockville, MD, USA). Cells were grown in Wil-
liam’s E and Ham’s F10 medium (1:1, v/v) supplemented with pen-
icillin (200 U/ml), streptomycin (200 Wg/ml), 2.5% fetal bovine serum
and 2.5% newborn calf serum (serum-supplemented medium (SSM)).
All cell lines were propagated in a humidi¢ed 5% CO2 incubator at
37‡C.
2.3. Determination of cell proliferation by the 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) method
Cells were seeded into 96 well plates (8000/well) and were treated
daily with increasing concentrations of inhibitors (0^20 WM) or vehicle
in SSM medium. At each day, one plate was taken out and the
medium was replaced with 100 Wl MTT (0.5 mg/ml in RPMI 1640
medium without phenol red). After 4 h incubation at 37‡C, medium
was discarded, MTT reaction products were dissolved in 100 Wl
DMSO and the absorbance was measured at 490 nm with a Micro-
ELISA Auto Reader spectrophotometer (Dynatech, Alexandria, VA,
USA).
2.4. Speci¢c labelling and detection of isoprenylated Ras proteins
RTAC cells were plated on 60 mm Petri dishes and were treated at
con£uence (5U106 cells) as described previously [8,16]. Two consec-
utive treatments were carried out with 10 WM FTase inhibitors for
24 h followed by a second with 10 WM lovastatin. The cells were then
incubated in 2 ml culture medium with 30 WCi/ml [3H]FPP or
[3H]geranylgeranyl-pyrophosphate ([3H]GGPP) (17 Ci/mmol, Amer-
sham, UK) for 8 h. Cells were disrupted in 1 ml lysis bu¡er (phos-
phate-bu¡ered saline containing 1% (v/v) Triton X-100, 0.1% (w/v)
sodium dodecyl sulfate (SDS), 0.5% (w/v) deoxycholic acid, 1 mM
phenylmethylsulfonyl£uoride, 10 Wg/ml aprotinin, 10 Wg/ml leupeptin
and 10 Wg/ml pepstatin, pH 7.4). The cell debris were removed by
centrifugation at 3500Ug, 4‡C for 10 min and supernatants were
used for prenylated Ras analysis. Cell lysates were immunoprecipi-
tated with pan-Ras (Ab-3) monoclonal antibody (Oncogene Science,
Uniondale, NY, USA) as described before [8]. Bound proteins were
washed four times with lysis bu¡er and released by boiling in sample
bu¡er. Released proteins were separated on a 14% SDS-polyacryl-
amide gel electrophoresis (SDS-PAGE) and then electrotransferred
to Immobilon-P membranes (Millipore, Bedford, MA, USA). Mem-
branes were exposed on a phosphorimager (Beckman, Palo Alto, CA,
USA) tritium-speci¢c screen for 25 days.
2.5. Immunodetection of Ras proteins
Cells were disrupted in lysis bu¡er. Cellular proteins (RTAC or Y1,
5 Wg; T24, 20 Wg) were separated on 14% SDS-PAGE, transferred to
Immobilon-P membranes and immunoblotted with pan-Ras (Ab-3) or
speci¢c anti-Ki-Ras monoclonal antibody (Ab-1; Oncogene Science).
Positive reactions were visualized using peroxidase-conjugated goat
anti-mouse IgG (Sigma) and an enhanced chemiluminescence (ECL)
reaction system (Amersham).
2.6. Flow cytometry
RTAC cells were plated at 400 000 cells on 35 mm Petri dishes, in
SSM, and allowed to attach overnight. Cells were treated with vehicle
or inhibitors every 24 h for 48 h, harvested and 106 nuclei were
prepared and stained with propidium iodide as described [17]. Ali-
quots containing 104 nuclei were run in a FACstar £ow cytometer
(Becton-Dickinson). The proportions of cells in G0/G1, S and G2/M
were calculated using the CellFIT Cell-Cycle Analysis software (Ver.
2.0, Becton-Dickinson).
2.7. Activated MAP kinases immunoblotting
Cultured RTAC cells were treated as described under Section 2.5
and were lysed in lysis bu¡er with 2 mM EGTA, 2 mM EDTA and
500 WM sodium orthovanadate. Equal amounts of total proteins
(100 Wg) were separated on 10% SDS-PAGE and transferred to a
PVDF membrane. As loading control, constitutive Ras p21 was de-
tected in parallel for each sample with pan-Ras (Ab-3) antibody. For
the detection of the phosphorylated MAP kinases, we used the anti-
Fig. 1. BPHI FTase inhibitors and FTI-277 inhibit farnesyl but not
geranylgeranyl transfer to Ras in RTAC cells. (A) The molecular
structure of BPHI FTase inhibitors: RPR130401 and RPR115135.
(B and C) Cells were incubated with FTase inhibitors (10 WM) for
24 h, with lovastatin and FTase inhibitors (10 WM) for another 24 h
and with 30 WCi/ml [3H]FPP (B) or [3H]GGPP (C) for 8 h. Control
vehicle (lane 1), FTI-277 (lane 2), RPR130401 (lane 3) and
RPR115135 (lane 4). After immunoprecipitation, Ras proteins were
separated by SDS-PAGE and detected by autoradiography using a
tritium screen and a phosphorimager. Data are representatives of
three independent experiments.
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ACTIVE MAP kinase polyclonal antibody (25 ng/ml) raised against
the dually phosphorylated Thr/Glu/Tyr region (pT183EpY) within the
catalytic core of the active form of MAP kinase enzymes (Promega,
Madison, WI, USA). A secondary peroxidase-conjugated donkey
anti-rabbit IgG at 1:10 000 dilution (Promega) and an ECL system
were also used. In a separate experiment, we tested the speci¢city of
the activated MAP kinases detection, using serum-stimulated and
non-stimulated RTAC cells grown in serum-free medium. A polyclo-
nal antibody raised against total MAP kinase ERK 1 and detecting
also ERK 2 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) gave
a similar MAP kinase detection in both samples. However, the anti-
ACTIVE MAP kinase antibody leads to a signal only in the serum-
stimulated sample.
3. Results and discussion
3.1. BPHI FTase inhibitors block e⁄ciently the farnesyl but
not geranylgeranyl transfer to Ras in RTAC cells
The inhibitory e¡ect of the novel BPHI FTase inhibitors
RPR130401 and RPR115135 (Fig. 1A) and the CaaX pepti-
domimetic FTI-277 on farnesyl and geranylgeranyl transfer to
Ras was evaluated in whole cells by blocking endogenous
prenyl synthesis with lovastatin and providing [3H]FPP or
[3H]GGPP in cell culture medium. RPR130401 displayed the
most potent inhibitory e¡ect on farnesyl transfer to Ras (90%
at 1 WM and 95% at 10 WM). The other inhibitors,
RPR115135 and FTI-277 at 10 WM, showed also a clear in-
hibitory e¡ect of 81 and 60%, respectively (Fig. 1B). A label-
ling experiment with [3H]GGPP showed that Ras proteins are
geranylgeranylated in RTAC cells (Fig. 1C, lane 1). None of
the FTase inhibitors decreased the geranylgeranylation of Ras
(Fig. 1C). Consequently, BPHI and peptidomimetic FTase
inhibitors were highly speci¢c to FTase over GGTase-1 in
vivo. Thus, the geranylgeranyl transfer to Ras did not proceed
through FTase in whole cells.
3.2. RTAC cell proliferation is resistant to FPP-competitive
and peptidomimetic FTase inhibitors but is sensitive to
lovastatin and simvastatin
We next determined whether, at concentrations of FTI-277
and RPR130401 that are highly selective for FTase over
GGTase-1, these agents are capable of inhibiting prolifera-
tion. Fig. 2 shows that FTI-277 (10 WM) and RPR130401
(10 WM) inhibit RTAC cells proliferation by only 10 and
30%, respectively. The IC50 for RPR130401 is 30 WM. Simi-
larly, Fig. 2A,B shows that Y1 cells were not sensitive to FTI-
277 and RPR130401. Conversely, T24 cells were sensitive to
both FTase inhibitors in the 1^20 WM range. RPR130401 was
the most e⁄cient FTase inhibitor of proliferation of partly
resistant cells (RTAC and Y1 cells) but FTI-277 (1^10 WM)
was equally or even more e⁄cient (at 20 WM) than
RPR130401 on T24 sensitive cells. Ras analysis by SDS-
PAGE (Fig. 2D) showed abundant Ki-Ras protein in
RTAC and Y1 cells while Ki-Ras was absent in T24 cells
which express Ha-Ras-V12 [18,19]. These results suggest that
the lack of sensitivity of RTAC and Y1 cells is due to resist-
ance of Ki-RasB prenylation to FTase inhibitors.
Furthermore, RTAC cells were very sensitive to the HMG-
CoA inhibitors lovastatin (IC50 = 7 WM) and simvastatin
(IC50 = 2 WM, Fig. 2C). All together, these results suggest
Fig. 2. Proliferation of RTAC cells is partially resistant to FTase inhibitors but sensitive to HMG-CoA reductase inhibitors. (A and B) Partial
inhibition of cell proliferation by FTI-277 (A) and RPR130401 (B) (1, 10 and 20 WM) in RTAC and Y1 cells as compared to strong inhibition
in T24 cell lines. (C) E¡ect of lovastatin and simvastatin (1, 10 and 20 WM) on cell proliferation in RTAC cells. (*) Partial cell death observed.
Cells grown in 5% SSM were treated each day for 4 days with fresh medium and indicated concentrations of inhibitors. Cell numbers were
measured in octoplicate in 96 well plates as described under Section 2 and shown at day 4. (D) Immunodetection of p21 Ras proteins in
RTAC, Y1 and T24 cells with pan-Ras (Ab-3) and Ki-Ras antibodies. Data are representatives of three independent experiments.
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that an alternative prenylation to that catalyzed by FTase
may be involved in RTAC cell proliferation.
3.3. RTAC cell proliferation is blocked by GGTI-298 at high
concentrations and by the combined treatment with
FTase inhibitors and GGTI-298 at low, non-cytotoxic
concentrations
GGTI-298 (3^15 WM) inhibited RTAC cell proliferation in
a dose-dependent manner with an IC50 of 11 WM (Fig. 3A). A
slight cytostatic e¡ect (17%) was shown at 3 WM and a more
marked cytostatic e¡ect was observed at 10 WM (41%). Cells
treated with GGTI-298 (15 WM) for 4 days remained quies-
cent. However, on day 5, severe cell lysis occurred. GGTI-298
(10 WM) for up to 5 days showed no cytotoxicity. When com-
bined, GGTI-298 (10 WM) and RPR130401 (3 or 10 WM)
inhibited cell proliferation by 70 and 77%, respectively (Fig.
3B). Each inhibitor alone inhibited proliferation only by 35^
40% (Fig. 3B). Thus, both farnesylated and geranylgerany-
lated proteins are involved in RTAC cell proliferation.
3.4. FTase inhibitor RPR130401 and GGTI-298 co-treatment is
required for cell cycle arrest in the G0/G1 phase
Table 1 shows that co-treatment with RPR130401 and
GGTI-298, but not mono-treatment, resulted in an increase
of the percentage of cells in the G0/G1 phase of the cell cycle
from 58 to 76%. This value is similar to that obtained with
lovastatin at 20 WM (79%). Thus, lovastatin alone and a com-
bination of GGTI-298 and RPR130401 were able to arrest
cells in G0/G1. Furthermore, a marked amount of subdiploid
cells (16%) was also observed with GGTI-298 (15 WM) and
lovastatin (13% at 20 WM). This observation is in favor of an
apoptotic e¡ect of GGTI-298 at concentrations higher than 10
WM and is consistent with the cell lysis observed after a 4 day
treatment with 15 WM GGTI-298 (Fig. 3A).
3.5. Co-treatment of RPR130401 and GGTI-298 blocks
MAP kinase activation in RTAC cells
MAP kinases ERK 1 and ERK 2 were activated in RTAC
cells maintained in SSM, as measured by Western blotting
using an antibody speci¢c for dually phosphorylated
(pT183EpY) MAP kinases. This activation was blocked by
lovastatin (not shown) but not by RPR130401, FTI-277 or
GGTI-298 alone (Fig. 4). In contrast, a co-treatment with
Fig. 3. GGTI-298 alone (A) and combination of GGTI-298 and
RPR130401 (B) inhibit RTAC cell proliferation. (A) RTAC cells
were treated daily with the vehicle (a) or with GGTI-298 at 3 (F),
10 (R), 12 (b) and 15 (+) WM. (B) Cells were treated daily with ve-
hicle alone, inhibitors alone or in combination at the given concen-
trations (in WM). Cell numbers were measured each day in 96 well
plates with the MTT colorimetric method and shown for each day
(A) or at day 4 (B). Data are the mean of octoplicate measurements
and the data are representatives of three independent experiments.
Table 1
E¡ects of GGTase-1 and FTase inhibitors on cell cycle phase distribution in RTAC cells
Treatment WM G0/G1 (%) G2/M (%) Sub G1 (%)
Control a 58 30 1
Lovastatin 20 79 16 13
GGTI-298 3 59 28 4
10 62 26 5
15 62 27 16
FTI-277 3 57 29 3
10 60 30 4
RPR130401 3 58 30 1
10 66 30 2
GGTI-298/FTI-277 10/3 60 29 4
10/10 68 26 7
GGTI-298/RPR130401 10/3 75 23 3
10/10 76 21 4
RTAC cells were treated with either vehicle, inhibitors alone or a combination of GGTase-1 and FTase inhibitors each day for 2 days. Cell
cycle distribution was determined on 104 cells by DNA propidium iodide staining and £ow cytometry measurement as described under Section
2. Data are representatives of three separate experiments.
aDrug vehicle only.
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RPR130401 and GGTI-298 suppressed the MAP kinase acti-
vation. Thus, this shows that both a FTase inhibitor (BPHI)
and GGTase-1 inhibitor (GGTI-298) were required for dis-
rupting Ki-Ras protein signaling.
Our results clearly demonstrate that BPHI FTase inhibitors
are potent and selective at blocking farnesyl but not geranyl-
geranyl transfer to Ras in RTAC cells. This is consistent with
our in vitro data where BPHI resulted in inhibition of the
farnesylation of Ki-Ras in the nM range in a highly selective
manner (100-fold for FTase over GGTase-1) [11]. FTI-277
was also shown to be speci¢c for FTase (0.2 WM IC50 for
Ha-Ras processing) over GGTase-1 (40 WM IC50 for Rap1a
processing) [5]. Furthermore, our results are consistent with
¢ndings that Ki-Ras is geranylgeranylated by GGTase-1 in
cultured cells [20^22] and not by FTase. This occurs despite
the fact that this enzyme was able to transfer in vitro both
farnesyl and geranylgeranyl moieties from FPP and GGPP to
Ki-Ras proteins but with a higher Km for the latter [23^25].
Resistance of Ki-Ras-expressing RTAC cells to cell growth
inhibition by CaaX peptidomimetics and FPP-competitive in-
hibitors at concentrations that inhibit FTase but not GGTase-
1 suggests that Ras is geranylgeranylated and is capable of
inducing the activation of the mitogenic transduction cascade
downstream to MAP kinase which contributes to continued
proliferation. Geranylgeranylated Ras appears to be as e⁄-
cient as farnesylated Ras at activating MAP kinases, as evi-
dent by the fact that MAP kinases continue to be phospho-
rylated even in the presence of FTase inhibitors. Similarly,
when GGTase-1 was blocked by GGTI-298 at 10 WM, Ras
was still farnesylated by FTase and MAP kinases were
activated. At a higher concentration (15 WM), GGTI-298 in-
hibited cell proliferation. This is likely due to the inhibition of
geranylgeranylated proteins such as RhoA and Rac1 that are
involved in the cell cycle control and possibly apoptosis [26^
28]. More importantly, when both Ras farnesylation and its
alternative geranylgeranylation were blocked by a BPHI
FTase inhibitor and the CaaX peptidomimetic GGTI-298 at
not really cytotoxic and non-apoptotic concentrations, activa-
tion of MAP kinases was suppressed, the cell cycle was
blocked in the G0/G1 phase and cell proliferation was consid-
erably decreased.
Two binding sites, one for the isoprenoid and the other for
the CaaX peptide substrates, have been identi¢ed on the L
subunit of FTase by X-ray crystallography [29] and postulated
to reside on the related subunit of GGTase-1. The e⁄ciency of
the BPHI and GGTI-298 combination used in this study may
be explained by the absence of competition between the two
inhibitors since they bind two di¡erent sites on the respective
FTase and GGTase-1 enzymes. All together, these results sug-
gest that an e⁄cient strategy to block tumoral proliferation of
Ki-Ras-expressing cells is to combine FTase and GGTase-1
inhibitors acting on two types of sites of the two L subunits:
one binding to the isoprenoid site of the FTase L subunit
(FPP-competitive) and the second one binding to the protein
binding site of GGTase-1 L subunit (CaaX peptidomimetic).
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